Cited by 259Schizophrenia research and treatmentMental Health and PsychiatryTreatment of Major Depression

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses

Open access

Haddad, Peter M., Correll, Christoph U.·2018·Therapeutic Advances in Psychopharmacology

DOI 10.1177/2045125318781475PMC PMC6180374

Open this paper in CoChat — free account Open PDF

Abstract

Schizophrenia is the eighth leading cause of disability worldwide in people aged 15–44 years. Before antidopaminergic antipsychotics were introduced in the 1950s, no effective medications existed for the treatment of schizophrenia. This review summarizes key meta-analytic findings regarding antipsychotic efficacy in the acute treatment of schizophrenia, including clozapine in treatment-resistant patients. In the most comprehensive meta-analysis of randomized controlled trials conducted in multi-episode schizophrenia, antipsychotics outperformed placebo regarding total symptoms, positive symptoms, negative symptoms, depressive symptoms, quality of life and social functioning. Amongst these outcomes, the standardized mean difference for overall symptoms was largest, that is, 0.47 (95% credible interval = 0.42–0.51), approaching a medium effect size, being reduced to 0.38 when publication bias and small-trial effects were accounted for. A comparison of two meta-analyses indicated that first-episode patients, compared with multi-episode patients, were more likely to have at least minimal treatment response [⩾20% Positive and Negative Syndrome Scale (PANSS)/Brief Psychiatric Rating Scale (BPRS) score reduction: 81% versus 51%] and good response (⩾50% PANSS/BPRS score reduction: 52% versus 23%). In multi-episode schizophrenia, no response or worsening after 2 weeks of a therapeutic antipsychotic dose was highly predictive of not achieving a good response at endpoint (median treatment = 6 weeks: specificity = 86%; positive predictive value = 90%), suggesting a change in treatment should be considered in such cases. In first-episode psychosis, adequately dosed antipsychotic treatment trials for more than 2 weeks are recommended before using no response or worsening as a decision point for aborting a given antipsychotic. In clearly defined treatment-resistant schizophrenia, clozapine generally outperformed other antipsychotics, especially when dosed appropriately (target = 3–6 months’ duration; trough clozapine level ⩾350–400 μg/L) with a response rate (⩾20% PANSS/BPRS) of 33% by 3 months of treatment. High antipsychotic doses and psychotropic combinations are unlikely to be superior to standard doses of antipsychotic monotherapy. Acute antipsychotic efficacy in schizophrenia depends on the targeted symptom domain (greater efficacy: total and positive symptoms, lesser efficacy: negative symptoms, depressive symptoms, social functioning and quality of life). Greater antipsychotic efficacy is associated with higher total baseline symptom severity, treatment-naïveté/first-episode status, shorter illness duration, and trials that are nonindustry sponsored and that have a lower placebo effect. The heterogeneity of antipsychotic response across individuals and key symptom domains, the considerable degree of nonresponse/treatment resistance in multi-episode patients, and the adverse effect potential of antipsychotics are major limitations, underscoring the need to develop new medications for the treatment of schizophrenia. Drug development should include matching patient subgroups, which are identified by means of clinical and biomarker variables, to mechanisms of action of novel medications, targeting specific symptom domains, and investigating mechanisms of action other than dopaminergic blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1177/2045125318781475

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,350
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595
Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population
Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K. I., Isometsä, E. T., Pirkola, S. P., Partonen, T., Tuulio‐Henriksson, A., Hintikka, J., Kieseppä, T., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.1.19 · Cited by 1,523
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,328
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.
Perkins, D., Gu, H., Boteva, K., & Lieberman, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1785 · Cited by 1,304
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
Howes, O. D., McCutcheon, R. A., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,187
Self-citation
Schizophrenia
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer‐Lindenberg, A., Weinberger, D. R., Cannon, T. D., O’Donovan, M. C., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,163
Self-citation

Flagged first, then by citations

Show all 74 references

Research works printed but not linked: 12

World Health Organisation, 2001, The WHO World Health Report 2001 - Mental Health: New Understanding, New Hope
A full list of the papers available in the Special Collection on Antipsychotics: Advances, Limitations, and Alternatives in Therapeutic Advances in Psychopharmacology is available at: http://journals.sagepub.com/page/tpp/special-collection/antipsychotics
10.1176/ajp.2006.163.4.743 · DOI
Royal College of Psychiatrists, 2014, CR190 Consensus statement on High-dose Antipsychotic medication
Ackenheil M, 1977, Psychotherapeutic drugs: part II, 923
Idanpaan-Heikkila J, Lancet, 1975
National Institute for Health and Care Excellence (NICE), 2014, Clinical guideline [CG178]
10.1176/ajp.151.12.1744 · DOI
Albert C., 2017, Int J Mol Sci, 18
Zhao S, 2015, Cochrane Database Syst Rev
Dieterich M, 2017, Cochrane Database Syst Rev
Carmona VR, 2017, Int J Occup Med Environ Health, 30, 345

Sorted by citations

Items 101–200 of 259

Salivary cortisol response to psychosocial stress in patients with first-episode psychosis
Gajšak, L. R., Vogrinc, Ž., Ružić, M. Ć., Ružić, Bošnjak, D., Kuharić, Bošković, M., Makar, A. K., Makar, Makarić, P., et al. (2021) · Croatian Medical Journal · doi:10.3325/cmj.2021.62.80 · Cited by 6
Pharmacological interventions for social cognitive impairments in schizophrenia: A protocol for a systematic review and network meta-analysis
Yamada, Y., Okubo, R., Tachimori, H., Uchino, T., Kubota, R., Okano, H., Ishikawa, S., Horinouchi, T., Takanobu, K., Sawagashira, R., et al. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.878829 · Cited by 8
Clozapine-Induced Constipation: A Case Report and Review of Current Management Guidelines
Patel, R. S., Veluri, N., Suchorab, A., Shah, K., & Verma, G. (2021) · Cureus · doi:10.7759/cureus.14846 · Cited by 7
Clozapine as a mood stabiliser for schizoaffective disorder: Effectiveness during a three-month follow-up
Peraire, M., Arnau, F., Benito, A., Fuertes-Sáiz, A., Almodóvar-Fernández, I., & Haro, G. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111090 · Cited by 6
Effects of several atypical antipsychotics closapine, sertindole or ziprasidone on hepatic antioxidant enzymes: Possible role in drug-induced liver dysfunction
Arizanović, L. P., Nikolić‐Kokić, A., Brkljačić, J. M., Tatalović, N., Miler, M., Oreščanin-Dušić, Z., Uzelac, T. V., Nikolic, M. R., Milošević, V., Blagojević, D. P., et al. (2020) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2020.1844827 · Cited by 6
Quantification of antipsychotic biotransformation in brain microvascular endothelial cells by using untargeted metabolomics
Ngamratanapaiboon, S., & Yambangyang, P. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01101 · Cited by 6
Network Analysis of the Structure of the Core Symptoms and Clinical Correlates in Comorbid Schizophrenia and Gambling Disorder
Granero, R., Fernández‐Aranda, F., Demetrovics, Z., Lara-Huallipe, M. L., Morón-Fernández, A., & Jiménez‐Múrcia, S. (2022) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-022-00983-y · Cited by 8
Anthocyanins from Aristotelia chilensis Prevent Olanzapine-Induced Hepatic-Lipid Accumulation but Not Insulin Resistance in Skeletal Muscle Cells
del Campo, A., Salamanca, C., FAJARDO, Á., Díaz‐Castro, F., Bustos, C., Calfío, C., Troncoso, R., Pastene, E., Acuña‐Castillo, C., Milla, L. A., et al. (2021) · Molecules · doi:10.3390/molecules26206149 · Cited by 6
Mediating roles of positive reappraisal and stigma resistance in the relationship between mindfulness and quality of life among stable schizophrenia patients
Aliche, C. J., Ifeagwazi, C. M., Nwamarah, J. U., Okechukwu, F. O., & Ngwu, E. C. (2023) · Current Psychology · doi:10.1007/s12144-023-04563-8 · Cited by 6
A Review of Pharmacokinetic and Pharmacodynamic Properties of Quetiapine IR and XR: Insights and Clinical Practice Implications
Joshi, K., Rao, S., & Mehta, S. C. (2025) · Cureus · doi:10.7759/cureus.86258 · Cited by 5
Enhancing Cognitive Functioning in Schizophrenia Through Occupational Therapy Interventions: A Systematic Review
Stratou, E., Gerosideris, N., Daskalou, S. D., & Katsouri, I.-G. (2025) · OTJR Occupational Therapy Journal of Research · doi:10.1177/15394492251353567 · Cited by 6
Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study
Chen, P., Chiu, C., Chang, C., Lu, M., Huang, C., Chen, C.-H., & Huang, M. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231225610 · Cited by 5
Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol
Jieu, B., Sykorova, E. B., Rohleder, C., Marcolini, E., Hoffmann, A., Koethe, D., Leweke, F. M., & Couttas, T. A. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116005 · Cited by 6
Pharmacist-led Si-care (schizophrenia care) model to improve medication adherence and symptom management in schizophrenia
Cahaya, N., Kristina, S. A., Widayanti, A. W., & Green, J. (2024) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2024.100544 · Cited by 7
Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes
Pungor, K., Bozikas, V. P., Emsley, R. A., Llorca, P., Gopal, S., Mathews, M., Wooller, A., & Bergmans, P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981500 · Cited by 5
How Would You Like to Take Your Medicine 2 Times a Year? Paliperidone Palmitate Every 6 Months for the Maintenance Treatment of Schizophrenia
Faden, J., & Citrome, L. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.02.003 · Cited by 5
Electrode montage for transcranial direct current stimulation governs its effect on symptoms and functionality in schizophrenia
Yamada, Y., Narita, Z. C., Inagawa, T., Yokoi, Y., Hirabayashi, N., Shirama, A., Sueyoshi, K., & Sumiyoshi, T. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1243859 · Cited by 5
Hyperlearning Hypothesis: Network disruption and maladaptive learning in schizophrenia
Yuichi, T., Sunaga, M., Fujihara, K., Ohki, T., Kato, Y., & Jinde, S. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111599 · Cited by 4
Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia
Sun, W., Jin, T., Yang, H., Li, J., Tian, Q., Gao, J., Peng, R., Zhang, G., & Zhang, X. (2024) · Schizophrenia · doi:10.1038/s41537-023-00425-1 · Cited by 3
A Mobile Health Intervention to Support Collaborative Decision-Making in Mental Health Care: Development and Usability
Romm, K. L., Skoge, M., Barrett, E. A., Berentzen, L., Bergsager, D., Fugelli, P., Bjella, T. D., Gardsjord, E. S., Kling, K., Kruse, S. H., et al. (2025) · JMIR Formative Research · doi:10.2196/57614 · Cited by 7
Case report: application of pharmacogenetics in the personalized treatment of an elderly patient with a major depressive episode
Pjevac, M., Redenšek, S., Blagus, T., Dolžan, V., & Bon, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250253 · Cited by 4
Chronic Methamphetamine and Psychosis Pathways
Hogarth, S. J., Manning, E. E., & van den Buuse, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_110-1 · Cited by 4
Yoga-Based Group Intervention for Inpatients with Schizophrenia Spectrum Disorders—Feasibility, Acceptability, and Preliminary Outcomes of a Rater-Blinded Randomized Controlled Trial.
Hahne, I., Zierhut, M., Bergmann, N., Hahn, E., Ta, T. M. T., Calvano, C., Bajbouj, M., & Böge, K. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae198 · Cited by 4
Evaluation of Prescription Patterns of Antipsychotics in Schizophrenia Patients—A Single-Center Prospective Study
Mohamed, A., Almulhim, A., Alnijadi, A. A., Aziz, F. B. A., Alajmi, K. K., Al-Mudhaffar, A. A., & Almutairi, M. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14092941 · Cited by 3
Brain age gap reduction following exercise mirrors clinical improvements in schizophrenia spectrum disorders
Yilmaz, D., Papiol, S., Keeser, D., Cole, J. H., Malchow, B., Walter, H., Meyer‐Lindenberg, A., Hirjak, D., Hasan, A., Schmitt, A., et al. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103881 · Cited by 7
Pharmacogenomics to optimise psychotropic prescribing: a survey of mental health professionals’ perceptions, knowledge, and educational needs
Panconesi, D., Murtough, S., Cotic, M., Khani, N. S., Varney, L., Richards-Brown, M., Abidoph, R., Mills, D., Richards‐Belle, A., Molai, J., et al. (2026) · The Pharmacogenomics Journal · doi:10.1038/s41397-025-00394-x · Cited by 3
Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine
Pieri, M. D., Ferrari, M., Marino, F., Traber, R., Bolla, E., & Cosentino, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182393 · Cited by 3
Personality disorders and schizophrenia spectrum disorders in the Italian forensic psychiatric population: clinical features, pattern of violence and treatment
Margari, A., Catanesi, R., Carabellese, F., Buongiorno, L., Piarulli, F. M., & Mandarelli, G. (2023) · International Review of Psychiatry · doi:10.1080/09540261.2023.2287095 · Cited by 5
The effect of functional magnetic resonance imaging connectivity on resting motor threshold transcranial magnetic stimulation in schizophrenia participants
Lewis, C. J., Mittal, N., Pandurangi, A. K., Mehta, U. M., & Hadimani, R. L. (2024) · AIP Advances · doi:10.1063/9.0000697 · Cited by 3
Interaction between baseline BMI and baseline disease severity predicts greater improvement in negative symptoms in first-episode schizophrenia
Sun, X., He, R., Xiao, Y., Xiu, M., Sun, M., Wu, F., & Zhang, X. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01763-6 · Cited by 3
Childhood trauma types in relation to antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, randomized controlled study
Mørkved, N., Johnsen, E., Kroken, R. A., Joa, I., Kjelby, E., Rettenbacher, M. A., Bartz-Johannessen, C. A., & Løberg, E. M. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116169 · Cited by 3
Longitudinal trends in schizophrenia among older adults: a 12-year analysis of prevalence and healthcare utilization in South Korea
Park, J. S., Kim, S., Choi, J. P., Kim, M.-S., Lee, Y. S., Joo, E.-J., Kim, Y. S., Lee, J., & Kim, S. H. (2025) · Schizophrenia · doi:10.1038/s41537-025-00575-4 · Cited by 3
Attitudes of Australian patients receiving inpatient mental health care towards deprescribing: a cross-sectional survey
Law, R., Gupta, N., Langford, A. V., & Reeve, E. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06717-3 · Cited by 3
α7 nicotinic acetylcholine receptor, activated glia, and cognitive impairment in schizophrenia: a dual-tracer PET study
Wakuda, T., Yokokura, M., Magata, Y., Suzuki, C., Murayama, C., Goto, T., Tamayama, T., Kameno, Y., Iwabuchi, T., Isobe, T., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03162-2 · Cited by 3
Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study
Caligiuri, M. P., Weiden, P. J., Legedza, A., Yagoda, S., & Claxton, A. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac018 · Cited by 4
Homocysteine Levels and Clinical Outcomes in Schizophrenia—A Pilot Randomized Controlled Trial
Vedam, V. A. V., Ghanta, M. K., Kantipudi, S. J., David, D. C., Vijayalakshmi, M., & Nuthalapati, P. (2022) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x221128649 · Cited by 3
A response to criticism of the global mental health movement. How polarization can be overcome in theory and in west African social psychiatric practice
Huppertz, M. (2024) · Cambridge Prisms Global Mental Health · doi:10.1017/gmh.2024.120 · Cited by 3
Pre- and Post- COVID-19 Pandemic Pneumonia Rates in Hospitalized Schizophrenia Patients
Miron, A. A., Ifteni, P. I., Lungu, A.-E., Dragomirescu, E., Dima, L., & Teodorescu, A. (2025) · Medicina · doi:10.3390/medicina61071251 · Cited by 3
Randomised controlled trial of clozapine in resistant schizophrenia and schizoaffective disorder
Peraire, M., Arnau, F., Villar-García, M., Benito, A., Echeverria, I., & Haro, G. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251355602 · Cited by 3
Pharmacogenomics and antipsychotics: efficacy and adverse drug reactions
Tsermpini, E. E., Terzi, T., Plesničar, B. K., & Dolžan, V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-819602-1.00010-3 · Cited by 3
Brain Age Gap Reduction Following Physical Exercise Mirrors Negative Symptom Improvement in Schizophrenia Spectrum DisordersPreprint
Yilmaz, D., Papiol, S., Keeser, D., Cole, J. H., Malchow, B., Schmitt, A., Falkai, P., Maurus, I., & Roell, L. (2025) · medRxiv · doi:10.1101/2025.01.08.24319554 · Cited by 3
Genetic architecture of RNA editing, splicing and gene expression in schizophrenia
Choudhury, M., Yamamoto, R., & Xiao, X. G. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae172 · Cited by 2
Association of core brain networks with antipsychotic therapeutic effects in first-episode schizophrenia
Luo, Y., Zhu, T., Zhang, Y., Fan, J., Zuo, X., Feng, X., Gong, J., Yao, D., Wang, J., & Luo, C. (2025) · Cerebral Cortex · doi:10.1093/cercor/bhaf088 · Cited by 2
Antipsychotics and dietary interventions: Pharmacodynamics, pharmacokinetics, and synergisms in therapy
Perrotta, C., Carnovale, C., Pozzi, M., Palma, C. D., Cervia, D., Nobile, M., & Clementi, E. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100061 · Cited by 3
Antipsychotic Acute-Phase Treatment in Individuals With and Without Recent Treatment
Brandt, L., Efthimiou, O., Siafis, S., Schneider‐Thoma, J., Stuke, H., Ayrilmaz, H., Hasan, A., Heinz, A., Gutwinski, S., Kane, J. M., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0587 · Cited by 2
The Association of Antipsychotic Treatment and Side Effects With Societal Recovery and Happiness: A Naturalistic Cohort Study of People in Long-term Care for a Psychotic Disorder
Crutzen, S., Gangadin, S. S., Hua, K. H., Visser, E., Jörg, F., Pijnenborg, G. H. M., van der Meer, L., Veling, W., & Castelein, S. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf122 · Cited by 2
Patient Life Engagement and Metabolic Profile Improve After Switching from First-/Second-Generation Antipsychotics to Brexpiprazole: A Real-World Study in Patients with Schizophrenia
Nicola, M. D., Pepe, M., Milintenda, M., Massetti, M., Moccia, L., Panaccione, I., & Sani, G. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15110502 · Cited by 3
Multimodal neuroimaging reveals brain neurochemical disturbances associated with superoxide dismutase in first-episode drug-naïve schizophrenia
Zhu, Z., Wang, Z., Yuan, X., Zou, Y., Zheng, C., Wen, Y., Hei, G., Song, X., & Shi, Y. (2026) · Translational Psychiatry · doi:10.1038/s41398-025-03801-w · Cited by 2
Differential Effects of Illness and Antipsychotics on Cortical Thinning in First-Episode Psychosis: A Randomized, Placebo-Controlled Magnetic Resonance Imaging Study
Chopra, S., Holmes, A., Segal, A., Zhang, X.-H., Francey, S. M., O'Donoghue, B. N., Cropley, V., Nelson, B., Graham, J., Baldwin, L., et al. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.028 · Cited by 5
Terapias de Terceira Geração nas Perturbações Psicóticas
Gomes, M., & FERNANDES, N. G. D. A. (2022) · Revista Portuguesa de Psiquiatria e Saúde Mental · doi:10.51338/rppsm.319 · Cited by 2
The Association between Schizophrenia Clinical Severity and Obesity Risk: A Literature Review
Li, I., & Hester, J. (2021) · Journal of Student Research · doi:10.47611/jsrhs.v10i4.2063 · Cited by 2
Does Electroencephalography Seizure Duration Account for an Adequate Treatment of Magnetic Seizure Therapy for Schizophrenia?
Jiang, J., Li, J., Xu, Y., Zhang, B., Sheng, J., Liu, D., Wang, W., Yang, F., Guo, X., Li, Q., et al. (2024) · Journal of Ect · doi:10.1097/yct.0000000000001047 · Cited by 2
Change in Clinical Risk Factors During Stay and Treatment in a Penitentiary Psychiatric Center
Slootmaker, J., van Koppen, M. V., & Harte, J. M. (2024) · International Journal of Offender Therapy and Comparative Criminology · doi:10.1177/0306624x241282279 · Cited by 2
Identification of Factors to Predict Transition to Schizophrenia in Subjects with Ultra-high Risk for Psychosis: A Protocol for a Multicenter, Longitudinal Study of Sleep Parameters and Cytokine Levels
Yamada, Y., Mishima, K., Ohnishi, T., Suzuki, M., Nemoto, T., Mizuno, M., Kishimoto, T., Tomita, H., Ozone, M., Kitamura, S., et al. (2024) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.24.1239 · Cited by 3
Clozapine and rapamycin reverse behavioral abnormalities in an animal model of autoimmune schizophrenia
Liu, D., Zhu, C., & Wei, H. P. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110286 · Cited by 3
Placebo and nocebo phenomena in schizophrenia spectrum disorders: a narrative review on current knowledge and potential future directions
Pujji, S. D., Colloca, L., & Waltz, J. A. (2025) · Psychological Medicine · doi:10.1017/s0033291725100901 · Cited by 2
Off-label antipsychotics prescription to adolescents with acute psychotic episodes does not cause adverse drug reactions
Ivashchenko, D. V., Buromskaya, N. I., Malakhova, A. D., Царькова, Н. А., Savchenko, L. M., Shevchenko, Y. S., & Sychev, D. A. (2021) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2021-3-19-26 · Cited by 2
Weekly Supervised Administration of Oral Antipsychotics: An Alternative to Long-Acting Injections?
Brissos, S., & Taylor, D. M. (2022) · CNS Drugs · doi:10.1007/s40263-022-00906-4 · Cited by 2
First-generation antipsychotics use and reduced risk of pneumonia—Clinical implications in SARS-CoV2 treatment: A systematic review and meta-analysis of observational studies
Eby, A., Jacob, E., & George, P. S. G. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2022.120917 · Cited by 2
Infra-Low Frequency Neurofeedback rapidly ameliorates schizophrenia symptoms: A case report of the first session
Nestoros, J. N., & Vallianatou, N. G. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.923695 · Cited by 2
The effect of baseline antipsychotic status on the 12‐month outcome in initially stabilized patients with schizophrenia
Fountoulakis, K. Ν., Panagiotidis, P., & Nimatoudis, I. (2019) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2712 · Cited by 2
Psychometric instruments for the assessment of depressive symptoms in patients with delusional disorder: A systematic review
González-Rodríguez, A., Monreal, J. A., Porras‐Segovia, A., Cervilla, J. A., & Gutiérrez-Rojas, L. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114435 · Cited by 1
Chronic Methamphetamine and Psychosis Pathways
Hogarth, S. J., Manning, E. E., & van den Buuse, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_110 · Cited by 1
Short-term Clinical Outcome of Previously Untreated and Treated Schizophrenia and Impact of Duration of Untreated Psychosis
Bansal, P., Saini, B., Sharma, A. K., Bansal, P. D., Moria, K., Saini, S., & Singh, B. (2023) · Indian Journal of Psychological Medicine · doi:10.1177/02537176221141614 · Cited by 1
Comparing the medication costs of treating patients with schizophrenia who use cannabis with those who do not
Nowbath, N., Abdelatif, N., & Lippi, G. (2024) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v30i0.2211 · Cited by 1
Del delirio a la flexibilidad psicológica: aplicación de la terapia de aceptación y compromiso
Palacios, A. A., El-Shahat, O. S., & Fraguela, J. A. G. (2025) · Clínica Contemporánea · doi:10.5093/cc2025a2 · Cited by 1
Safety Profile of Antipsychotics as Predictors of the Quality of Life in Patients with Schizophrenia—An Inpatient Welfare Institution-Based Cross-Sectional Study
Petrovic, A. D., Barjaktarevic, A. M., Kostic, O. Z., Mijailovic, S. S., Јаnkovic, S., Andjelkovic, M. V., Stanojević-Pirković, M., Parezanović-Ilić, K., Janjic, V. S., Desnica, J., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18060777 · Cited by 1
Clinical practice and metabolic consequences of olanzapine use in schizophrenia: results from a national survey in Spain
Muñoz-Manchado, L. I., Bernardo, M., Moreno, J. M. V., & Fernández-Egea, E. (2025) · The European Journal of Psychiatry · doi:10.1016/j.ejpsy.2025.100323 · Cited by 1
Perceptions and practices of long-acting injectable antipsychotic administration in community pharmacies within Washington State: A qualitative implementation science study
English, C., Helfrich, C. D., Bacci, J. L., Fox, J., & Mog, A. C. (2025) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2025.102974 · Cited by 1
Management of schizophrenia patients in acute setting – a multinational survey of prescription patterns in five European countries
Bioque, M., Amerio, A., Ustohal, L., Urban‐Kowalczyk, M., Petrikis, P., Álvarez‐Barón, E., & Gabarda-Inat, I. (2025) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2025.2594101 · Cited by 1
Cannabidiol for psychotic disorders: A meta-analysis of randomized controlled trials
Marchi, M., Rachedi, K., Bof, A., Mele, G., Pingani, L., Ferrari, S., & Galeazzi, G. M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261430501 · Cited by 1
Antipsychotic Drug Action, Novel Treatment Targets, and the Failure of Current Clinical Trial Designs in Evaluating New Target Molecules
Grace, A. A., & Uliana, D. L. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.010 · Cited by 1
The hippocampus as a generative model
Nalluru, S., Glitz, L., Przygodda, X., Mancini, V., & Barron, H. C. (2026) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2025.0247 · Cited by 1
Psychopharmacology: A Brief Overview of Its History
Foley, P. B. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_12-1 · Cited by 1
Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine)
McCutcheon, R. A., Kaar, S. J., & Howes, O. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.011 · Cited by 1
Clozapine
Drake, R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.012 · Cited by 1
Praktische Psychopharmakologie
Schu, U. (2021) · Elsevier eBooks · doi:10.1016/b978-3-437-21352-6.00008-0 · Cited by 1
Comparative Analysis of the Quality of Life of Schizophrenic Patients between Combination Therapy of Risperidone-Haloperidol and Clozapine-Risperidone-Haloperidol in a Mental Health Hospital in West Kalimantan Province
Anggriani, Y., Khairunisa, D., Wilson, W., & Andayani, N. (2022) · Indonesian Journal of Clinical Pharmacy · doi:10.15416/ijcp.2022.11.1.1 · Cited by 1
Psychopharmacology: A Brief Overview of Its History
Foley, P. B. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_12 · Cited by 1
Differential Treatment Responses in Pakistani Schizophrenia Samples: Correlation with Sociodemographic Parameters, Drug Addiction, Attitude to the Treatment and Antipsychotic Agents
Habiba, U., Malik, A., Raja, G. K., Memon, M. R., Nizami, A. T., Ishaq, R., Ilyas, M., Valadi, H., Nawaz, M., & Shaiq, P. A. (2023) · Brain Sciences · doi:10.3390/brainsci13030407 · Cited by 3
An Updated Review of Werner Janzarik’s Psychopathological Model of Endogenous (Idiopathic) Psychoses
Luche, R. D., Giovannini, S., & Maggini, C. (2023) · American Journal of Psychiatry and Neuroscience · doi:10.11648/j.ajpn.20231103.11 · Cited by 1
Adli Toksikoloji: Temel Kavramlar ve Prensipler
Bavunoğlu, I., Genç, M. K., Yayla, M., Açıkkol, M., Zengin, S., Şimşek, S. Z., Bülbül, T. T., & Arslan, Z. (2023) · doi:10.5152/6400 · Cited by 1
Adli Toksikolojide Analiz Yöntemleri
Bülbül, T. T., & Türkmen, Z. (2023) · doi:10.5152/6406 · Cited by 1
Talking to the most reasonable voice: building rapport within a crisis service
Ilola, E., & Howe, A. J. (2024) · Psychoanalytic Psychotherapy · doi:10.1080/02668734.2024.2317695 · Cited by 1
Potential impact on mental health in patients with treatment-resistant schizophrenia - clozapine augmentation with long-acting parenteral antipsychotics: a case series
Nováková, M., Hammer, T., Nováková, E., Mayerová, M., Ustohal, L., & Kotolová, H. (2023) · Česká a slovenská farmacie · doi:10.5817/csf2023-6-276 · Cited by 1
Antipsychotic Drugs
Kshirsagar, S. N., & Sahoo, T. K. (2024) · Springer eBooks · doi:10.1007/978-981-99-8059-8_25 · Cited by 1
Validation of behavioral measures of social cognition in individuals diagnosed with schizophrenia
Rahamim, N., Gilad, R., Linkovski, O., Bergman, H., Avirame, K., Foul, Y. A., & Eitan, R. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1443145 · Cited by 2
Promising novel drug delivery approaches in the development of therapeutics for schizophrenia disease management
Shareena, G., & Kumar, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00026-3 · Cited by 1
Molecular and topographic mapping of antipsychotic effects: a meta-analysis of postsynaptic density proteins in animal models with translational implications
Simone, G. D., Prisco, M. D., Oliva, V., Vellucci, L., Ciccarelli, M., Mazza, B., Fico, G., Fornaro, M., Iasevoli, F., Vieta, E., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03351-z · Cited by 2
Drugs for Treatment of Schizophrenia
Seifert, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-18899-3_29 · Cited by 1
Psychiatry: The State of the Art
Fountoulakis, K. Ν. (2021) · Springer eBooks · doi:10.1007/978-3-030-86541-2_18 · Cited by 2
Classification of schizophrenia spectrum disorder using machine learning and functional connectivity: reconsidering the clinical applicationPreprint
Li, C., Wang, F., Jiang, X., Chen, J., Duan, J., Han, S., Yan, H., Tang, Y., & Ke Cheng, X. U. (2020) · medRxiv · doi:10.1101/2020.05.30.20118026 · Cited by 1
Risk factors for violent behavior in people with psychotic disorders
Lamsma, J. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/496 · Cited by 1
Psychosis
Khanth, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-38971-9_455-1 · Cited by 1
How many clients with refractory psychosis are eligible for both cognitive-behaviour therapy and clozapine? A chart-review study
Erickson, D. H., & Procyshyn, R. M. (2019) · Cogent Psychology · doi:10.1080/23311908.2019.1611208
Evidence-based treatment of acute psychotic episode and schizophrenia in children and adolescents
Ivashchenko, D. V., Buromskaya, N. I., Tazagulova, M. K., Tutova, A. D., Savchenko, L. M., Shevchenko, Y. S., & Sychev, D. A. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2019119121132
Is high-dose maintenance therapy effective in treatment-refractory psychosis? A case series
Shad, M. U. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.01.018
From the Second Half of the Twentieth Century to the Early Twenty-First: The Psychopharmacologic Era
Fountoulakis, K. (2021) · Psychiatry · doi:10.1007/978-3-030-86541-2_11 · Cited by 1
Disastrous Events in Phanerozoic History of the Earth and the Sun Motion in the Galaxy
Goncharov, G. N., & Орлов, В. В. (2004) · ASPC
“Golden Shot” in the Treatment and Diagnosis of Schizophrenia: Psychiatrists or Neuroscientists?
Dubatova, I. V., Antsyborov, L. A., Хейгетян, А. В., & Antsyborov, A. V. (2021) · Interactive science · doi:10.21661/r-555399

Authors: Haddad, P. M., & Correll, C. U.
Affiliations: University of Manchester (GB)
Hofstra University (US)
Corresponding author: Haddad, Peter M.
ORCID: Haddad, Peter M.
Correll, Christoph U.
Venue: Therapeutic Advances in Psychopharmacology
Publisher: SAGE Publications
Published: 2018-10-08
Volume: 8
Issue: 11
Pages: 303-318
ISSN: 2045-1253 (ISSN-L)
2045-1261
DOI: 10.1177/2045125318781475
PMC: PMC6180374
OpenAlex: W2897156727
Cited by: 259
References: 74
Citations by year: 2026: 31 · 2025: 36 · 2024: 45 · 2023: 46 · 2022: 31 · 2021: 33 · 2020: 23 · 2019: 12
FWCI: 2.58
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Therapeutic Advances in Psychopharmacology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, clozapine, treatment-resistant schizophrenia, first-episode psychosis, treatment response prediction, antipsychotic dosing, antipsychotic monotherapy, positive symptoms, negative symptoms, depressive symptoms, quality of life, social functioning, publication bias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks